Federal research funding for prostate cancer accounts for around $400 million per year. The Prostate Cancer Research Program at the Department of Defense has received about $80 million per year since 2001. Funding at the PCRP has accelerated the clinical trial process for several drugs over the past couple of years including the recently approved [...]
The long awaited FDA approval of Zytiga (abiraterone acetate), a once-daily oral agent, for the treatment of castration-resistant, metastatic prostate cancer following docetaxel chemotherapy has happened! Malecare celebrates this approval as it celebrates the significant numbers of new drug approvals we have had over the last year and one half. The approval of Zytiga represents [...]
As of now, Congress and the Administration are at an impasse on FY 11 spending. If no deal is reached by Friday, government operations will shut down. This would impact cancer research and prevention programs in the following ways: * Patient enrollment in clinical trials would be discontinued; * No new grants would be awarded; [...]
There has been some movement in the House of Representatives pertaining to the issue of future funding for the Department of Defense Prostate Cancer Research Program (DoD). The budget debate continues to slog on. We still could see an eventual governmental shut down if the members of congress are still unable to either pass a [...]
I have been writing about the dire need for us to reach out to our congressional delegates and demand they support funding for the Prostate Cancer Research Program (PCRP). If you have not yet contacted your congressional members, please do it. Don’t forget you also need to let your entire email list and address book [...]